A Phase 1, Open-Label, Dose-Escalation Study of PRT1419, a Selective Induced MCL-1 Inhibitor, in Patients With Advanced/Metastatic Solid Tumors

Disclosures

• G.S. Falchook: Royalties (Wolters Kluwer); advisory role (AbbVie, BostonGene, Fujifilm, Inspirna, Jubilant, Navire, Predicine, Regeneron, Silicon, Turning Point); speaker honoraria (Rocky Mountain Oncology Society, Total Health Conferencing); travel expenses (Amgen, BMS, EMD Serono, Fujifilm, Millennium, Sarah Cannon Research Institute, Synthorx/Sanofi); research funding (3-V Biosciences, Abbisko, AbbVie, ABL Bio, ADC Therapeutics, Accutar, Agenus, Aileron, ASCO, Amgen, ARMO/Eli Lilly, Artios, AstraZeneca, BeiGene, Bioatla, Bioinvent, Biothera, Bicycle, Black Diamond, Boehringer Ingelheim, Celgene, Celldex, Ciclomed, Curegenix, Curis, Cyteir, Daiichi, DelMar, eFFECTOR, Eli Lilly, EMD Serono, Epizyme, Erasca, Exelixis, Freenome, Fujifilm, Genmab, GSK, Hutchison MediPharma, IGM Biosciences, Ignyta, Immunitas, ImmunoGen/MacroGenics, Incyte, Jacobio, Jazz, Jounce, Jubilant, Kolltan, Loxo/Bayer, MedImmune, Merck, Metabomed, Millennium, Mirati, miRNA Therapeutics, Molecular Templates, NIH, Navire, NiKang, Novartis, OncoMed, Oncorus, Oncothyreon, Poseida, Precision Oncology, Prelude, PureTech, Pyramid, RasCal, Regeneron, Relay, Rgenix, Ribon, Samumed, Sapience, Seagen, Silicon, Simcha, Sirnaomics, Strategia, Syndax, Synthorx/Sanofi, Taiho, Takeda, Tallac, Tarveda, Teneobio, Tesaro, Tocagen, Turning Point, MD Anderson Cancer Center, Vegenics, Xencor, Zhuhai Yufan)
• M.R. Patel: Advisory role (Olema Pharmaceuticals); leadership (ION Pharma); honoraria (Janssen); research funding (Accutar Biotech, Acerta Pharma, Adagene, ADC Therapeutics, Agenus, Aileron Therapeutics, Artios, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, BioNTech AG, BioTheryX, Black Diamond Therapeutics, Blueprint Pharmaceuticals, Boehringer Ingelheim, Celgene, CicloMed, Clovis Oncology, Compugen, Cullinan Oncology, Cyteir Therapeutics, Daiichi Sankyo, Eli Lilly, Erasca, Inc, Evelo Therapeutics, Genetech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, IGM Biosciences, Immune-Onc Therapeutics, Immunogen, Jacobio, Janssen, Jazz Pharmaceuticals, Klus Pharma, Kymab, Loxo, LSK Biopartners, Lycera, MabSpace Biosciences, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix, Olema, ORIC Pharmaceuticals, Pfizer, Pionyr, Prelude Therapeutics, Puretech, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Samumed, Seven and Eight Biopharmaceuticals, Silicon Therapeutics, Step Pharma, Syndax, Synthorx, Taiho Pharmaceutical, TeneoBio, Tesaro, TopAlliance BioSciences Inc., Treadwell Therapeutics, Vigeo, Xencor, Zymeworks)
• M. McKean: Research funding (Aadi Biosciences, Accutar Biotechnology, Alpine Immune Sciences, Arcus Biosciences, Arvinas, Ascentage Pharma Group, Astellas, Bayer, Bicycle Therapeutics, BioMed Valley Discoveries, BioNTech, Dragonfly Therapeutics, EMD Serono, Epizyme, Erasca, Exelixis, Foghorn Therapeutics, G1 Therapeutics, Genentech, Gilead Sciences, GlaxoSmithKline, IDEAYA Biosciences, Ikena Oncology, ImmVira Pharma, Infinity Pharmaceuticals, Jacobio Pharmaceuticals, Kechow Pharma, Kezar Life Sciences, Kinnate BioPharma, MedImmune, Mereo BioPharma, Metabomed, Moderna, NBE Therapeutics, Nektar, Novartis, OncoC4, Oncorus, PACT Pharma, Pfizer, Plexxikon, Poseida, Prelude Therapeutics, Pyramid Biosciences, Regeneron, Sapience, Scholar Rock, Seattle Genetics, Synthrox, Takeda, Teneobio, Tempest Therapeutic, Tizona Therapeutics, TMUNITY Therapeutics, TopAlliance Biosciences, Xilio); and consulting fees (Astellas Pharma, AstraZeneca, BicycleTx Limited, Castle Biosciences, Eisai, Ideaya Biosciences, iTeos, Moderna, Pfizer)
• A. Philipovskiy: No relevant potential conflicts of interest
• M. Milhem: Consulting fees (Amgen, Array, Biontech, Blueprints Medicine, Exicure, Immunocore, Novartis, Syneos, Trieza)
• N. Bhagwat, R. Chiaverelli, W. Sun, W. Novotny, M. Kurman, and S. Rowe: Employees of Prelude Therapeutics Inc., Wilmington, DE and may own stocks or shares
• M. Foster and D. Hunter are paid consultants of Prelude Therapeutics Inc., Wilmington, DE